Renaissance Technologies LLC Has $5.10 Million Stock Position in LifeStance Health Group, Inc. $LFST

Renaissance Technologies LLC increased its position in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) by 92.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 800,500 shares of the company’s stock after buying an additional 384,600 shares during the period. Renaissance Technologies LLC’s holdings in LifeStance Health Group were worth $5,099,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Larson Financial Group LLC raised its holdings in LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after acquiring an additional 3,791 shares during the period. KBC Group NV acquired a new position in LifeStance Health Group during the 1st quarter worth $29,000. Bayesian Capital Management LP acquired a new position in LifeStance Health Group during the 2nd quarter worth $52,000. PNC Financial Services Group Inc. boosted its holdings in LifeStance Health Group by 615.3% during the first quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock valued at $59,000 after acquiring an additional 7,987 shares during the period. Finally, Assetmark Inc. boosted its holdings in LifeStance Health Group by 17.0% during the first quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock valued at $60,000 after acquiring an additional 1,367 shares during the period. 85.50% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q2 earnings and revenue beat estimates: LifeStance reported adjusted earnings of $0.06 per share versus the $0.03 consensus estimate. Revenue rose 26% year over year to $435.4 million, above expectations of approximately $414.6 million. LifeStance Health Group Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Profitability improved sharply: The company swung to $23.6 million of net income from a $3.8 million loss a year earlier. Adjusted EBITDA nearly doubled to $66.0 million, or 15.2% of revenue, helped by higher revenue per visit, lower center costs and operating leverage. LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook
• Positive Sentiment: Growth metrics remained strong: Visit volume increased 19% to 2.6 million, while the clinician base expanded 11% to 8,542. Management said growth reflected clinician additions, better productivity and increased revenue per visit.
• Positive Sentiment: Full-year outlook was raised: LifeStance now expects 2026 revenue of $1.685 billion to $1.725 billion, Center Margin of $570 million to $594 million and adjusted EBITDA of $215 million to $235 million. Third-quarter revenue guidance of $420 million to $440 million also exceeds the prior consensus of roughly $417.7 million. The board additionally authorized a new $100 million share-repurchase program.
• Neutral Sentiment: Cash generation was a strength, but leverage remains relevant: Operating cash flow reached $99.9 million in Q2 and cash totaled $225.9 million at quarter-end, compared with $259.0 million of net long-term debt. The balance sheet supports continued investment and buybacks, although debt exceeds cash.
• Negative Sentiment: Investors should monitor execution risks: LifeStance remains exposed to clinician recruitment and retention, reimbursement pressure, healthcare regulation and competition. Reported insider activity also shows substantial selling by certain holders, which could create supply pressure even though it does not directly change operating performance.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Wall Street Zen lowered LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. KeyCorp increased their target price on LifeStance Health Group from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Canaccord Genuity Group increased their target price on LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. The Goldman Sachs Group started coverage on LifeStance Health Group in a report on Friday, June 5th. They issued a “neutral” rating and a $9.00 target price on the stock. Finally, JPMorgan Chase & Co. lifted their price target on LifeStance Health Group from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, LifeStance Health Group has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Insider Activity

In related news, Director Robert Bessler sold 894,337 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $10.13, for a total value of $9,059,633.81. Following the completion of the transaction, the director directly owned 539,763 shares of the company’s stock, valued at $5,467,799.19. This trade represents a 62.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Darren M. Black sold 5,899,661 shares of LifeStance Health Group stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $47,315,281.22. Following the sale, the director owned 23,310,115 shares in the company, valued at $186,947,122.30. This represents a 20.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 7,612,394 shares of company stock worth $62,938,451. Company insiders own 3.50% of the company’s stock.

LifeStance Health Group Price Performance

Shares of LifeStance Health Group stock opened at $10.66 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.48 and a quick ratio of 1.48. The company has a market cap of $4.13 billion, a PE ratio of 177.67 and a beta of 1.14. The firm has a fifty day moving average price of $9.88 and a two-hundred day moving average price of $8.03. LifeStance Health Group, Inc. has a fifty-two week low of $3.81 and a fifty-two week high of $11.76.

LifeStance Health Group (NASDAQ:LFST) last released its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The business had revenue of $435.35 million during the quarter, compared to analysts’ expectations of $414.58 million. During the same quarter last year, the company earned ($0.01) earnings per share. The firm’s revenue was up 26.1% on a year-over-year basis. Analysts expect that LifeStance Health Group, Inc. will post 0.12 EPS for the current year.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.